229 related articles for article (PubMed ID: 26861454)
1. Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer-Initiating Cells and Is a Potent Target of Immunotherapy.
Morita R; Hirohashi Y; Torigoe T; Ito-Inoda S; Takahashi A; Mariya T; Asanuma H; Tamura Y; Tsukahara T; Kanaseki T; Kubo T; Kutomi G; Mizuguchi T; Terui T; Ishitani K; Hashino S; Kondo T; Minagawa N; Takahashi N; Taketomi A; Todo S; Asaka M; Sato N
Clin Cancer Res; 2016 Jul; 22(13):3298-309. PubMed ID: 26861454
[TBL] [Abstract][Full Text] [Related]
2. Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells.
Morita R; Nishizawa S; Torigoe T; Takahashi A; Tamura Y; Tsukahara T; Kanaseki T; Sokolovskaya A; Kochin V; Kondo T; Hashino S; Asaka M; Hara I; Hirohashi Y; Sato N
Cancer Sci; 2014 Apr; 105(4):389-95. PubMed ID: 24450541
[TBL] [Abstract][Full Text] [Related]
3. Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules.
Tallerico R; Todaro M; Di Franco S; Maccalli C; Garofalo C; Sottile R; Palmieri C; Tirinato L; Pangigadde PN; La Rocca R; Mandelboim O; Stassi G; Di Fabrizio E; Parmiani G; Moretta A; Dieli F; Kärre K; Carbone E
J Immunol; 2013 Mar; 190(5):2381-90. PubMed ID: 23345327
[TBL] [Abstract][Full Text] [Related]
4. Exploring olfactory receptor family 7 subfamily C member 1 as a novel oral cancer stem cell target for immunotherapy.
Miyamoto S; Hirohashi Y; Morita R; Miyazaki A; Ogi K; Kanaseki T; Ide K; Shirakawa J; Tsukahara T; Murai A; Sasaya T; Koike K; Kina S; Kawano T; Goto T; Ntege EH; Shimizu Y; Torigoe T
Cancer Sci; 2023 Sep; 114(9):3496-3508. PubMed ID: 37344992
[TBL] [Abstract][Full Text] [Related]
5. DNA methyltransferase 1 is essential for initiation of the colon cancers.
Morita R; Hirohashi Y; Suzuki H; Takahashi A; Tamura Y; Kanaseki T; Asanuma H; Inoda S; Kondo T; Hashino S; Hasegawa T; Tokino T; Toyota M; Asaka M; Torigoe T; Sato N
Exp Mol Pathol; 2013 Apr; 94(2):322-9. PubMed ID: 23064049
[TBL] [Abstract][Full Text] [Related]
6. Ectopically expressed variant form of sperm mitochondria-associated cysteine-rich protein augments tumorigenicity of the stem cell population of lung adenocarcinoma cells.
Takahashi A; Hirohashi Y; Torigoe T; Tamura Y; Tsukahara T; Kanaseki T; Kochin V; Saijo H; Kubo T; Nakatsugawa M; Asanuma H; Hasegawa T; Kondo T; Sato N
PLoS One; 2013; 8(11):e69095. PubMed ID: 24244262
[TBL] [Abstract][Full Text] [Related]
7. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
Morrison BJ; Steel JC; Morris JC
BMC Cancer; 2018 Apr; 18(1):469. PubMed ID: 29699516
[TBL] [Abstract][Full Text] [Related]
8. An adoptive T cell immunotherapy targeting cancer stem cells in a colon cancer model.
Gao XY; Wang XL
J BUON; 2015; 20(6):1456-63. PubMed ID: 26854441
[TBL] [Abstract][Full Text] [Related]
9. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy.
Horibe R; Hirohashi Y; Asano T; Mariya T; Suzuki T; Takaya A; Saijo H; Shionoya Y; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Watanabe K; Atsuyama E; Toji S; Hirano H; Hasegawa T; Takahashi H; Sato N; Torigoe T
PLoS One; 2017; 12(3):e0171460. PubMed ID: 28248963
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells.
Inoda S; Hirohashi Y; Torigoe T; Morita R; Takahashi A; Asanuma H; Nakatsugawa M; Nishizawa S; Tamura Y; Tsuruma T; Terui T; Kondo T; Ishitani K; Hasegawa T; Hirata K; Sato N
Am J Pathol; 2011 Apr; 178(4):1805-13. PubMed ID: 21435460
[TBL] [Abstract][Full Text] [Related]
11. Establishment and Analysis of Cancer Stem-Like and Non-Cancer Stem-Like Clone Cells from the Human Colon Cancer Cell Line SW480.
Takaya A; Hirohashi Y; Murai A; Morita R; Saijo H; Yamamoto E; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Tamura Y; Takemasa I; Kondo T; Sato N; Torigoe T
PLoS One; 2016; 11(7):e0158903. PubMed ID: 27415781
[TBL] [Abstract][Full Text] [Related]
12. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.
Asano T; Hirohashi Y; Torigoe T; Mariya T; Horibe R; Kuroda T; Tabuchi Y; Saijo H; Yasuda K; Mizuuchi M; Takahashi A; Asanuma H; Hasegawa T; Saito T; Sato N
Oncotarget; 2016 Mar; 7(10):11223-37. PubMed ID: 26849232
[TBL] [Abstract][Full Text] [Related]
13. Identification and functional analysis of variants of a cancer/testis antigen LEMD1 in colorectal cancer stem-like cells.
Takeda R; Hirohashi Y; Shen M; Wang L; Ogawa T; Murai A; Yamamoto E; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Nishidate T; Okita K; Kutomi G; Sato N; Takemasa I; Torigoe T
Biochem Biophys Res Commun; 2017 Apr; 485(3):651-657. PubMed ID: 28219643
[TBL] [Abstract][Full Text] [Related]
14. GRIK2 has a role in the maintenance of urothelial carcinoma stem-like cells, and its expression is associated with poorer prognosis.
Inoue R; Hirohashi Y; Kitamura H; Nishida S; Murai A; Takaya A; Yamamoto E; Matsuki M; Tanaka T; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Sato N; Masumori N; Torigoe T
Oncotarget; 2017 Apr; 8(17):28826-28839. PubMed ID: 28418868
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
[TBL] [Abstract][Full Text] [Related]
16. GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy.
Miyata H; Hirohashi Y; Yamada S; Yanagawa J; Murai A; Hashimoto S; Tokita S; Hori K; Abe T; Kubo T; Tsukahara T; Kanaseki T; Shinohara N; Torigoe T
Cancer Immunol Immunother; 2022 Apr; 71(4):795-806. PubMed ID: 34405274
[TBL] [Abstract][Full Text] [Related]
17. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.
Pan QZ; Pan K; Wang QJ; Weng DS; Zhao JJ; Zheng HX; Zhang XF; Jiang SS; Lv L; Tang Y; Li YQ; He J; Liu Q; Chen CL; Zhang HX; Xia JC
Stem Cells; 2015 Feb; 33(2):354-66. PubMed ID: 25267273
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy sensitizes colon cancer initiating cells to Vγ9Vδ2 T cell-mediated cytotoxicity.
Todaro M; Orlando V; Cicero G; Caccamo N; Meraviglia S; Stassi G; Dieli F
PLoS One; 2013; 8(6):e65145. PubMed ID: 23762301
[TBL] [Abstract][Full Text] [Related]
19. FOXM1-Induced PRX3 Regulates Stemness and Survival of Colon Cancer Cells via Maintenance of Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Heo HJ; Kim HK; Bae KB; Park YH; Kim SU; Kim JM; Kim N; Ko KS; Rhee BD; Han J
Gastroenterology; 2015 Oct; 149(4):1006-16.e9. PubMed ID: 26091938
[TBL] [Abstract][Full Text] [Related]
20. Efficiency of G2/M-related tumor-associated antigen-targeting cancer immunotherapy depends on antigen expression in the cancer stem-like population.
Mori T; Nishizawa S; Hirohashi Y; Torigoe T; Tamura Y; Takahashi A; Kochin V; Fujii R; Kondo T; Greene MI; Hara I; Sato N
Exp Mol Pathol; 2012 Feb; 92(1):27-32. PubMed ID: 22001602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
